AstraZeneca Covid-19 vaccine is 70% effective on average, early data show
AstraZeneca said Monday that its coronavirus vaccine reduced the risk of Covid-19 infection by an average of 70.4%, according to an interim analysis of large Phase 3 trials conducted in the United Kingdom and Brazil.
The AstraZeneca vaccine, developed in partnership with Oxford University, is the third vaccine to announce positive clinical trial results this month. Two vaccine candidates, one from partners Pfizer and BioNTech and the other from Moderna, showed 95% efficacy against Covid-19 infections in their respective clinical trials.
Read Original Article: AstraZeneca Covid-19 vaccine is 70% effective on average, early data show »
